1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow NP-G2-044: new trials by email Literature Review of NP-G2-044 trials Research Report on NP-G2-044
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer | Phase 2 / Phase 3 | Active not recruiting | Novita Pharmaceuticals, Inc. | 380 | 2025-12-29 | 2026-03-09 |
| Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies NP-G2-044 - Breast Cancer, Pancreas Cancer | Phase 1 | Completed | Novita Pharmaceuticals, Inc. | 23 | 2017-12-21 | 2025-07-20 |
Ovarian Neoplasms (2) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Novita Pharmaceuticals, Inc. (2)
United States (2)
Jillian Zhang, Ph.D. (1) · Jillian Zhang, PhD (1) · Lisa Barroilhet, MD (1)